Download Center
You Have Requested The File: Diwali-Stock-Picks-2016-IDBI-Capital.pdf
| Subscribe To Our Free Newsletter |
Latest Stock Market News
Latest Articles
- Comment on Ace Stock Picker Maheen Rahman Recommends Mega Multibagger Stocks Which Will Be “Next HDFC Bank, Kotak Bank” by anil In reply to <a href="https://rakesh-jhunjhunwala.in/ace-stock-picker-maheen-rahman-recommends-mega-multibagger-stocks-which-will-be-next-hdfc-bank-kotak-bank/#comment-9729">Drjujgiv< .....
- Comment on telegram by Shaileshbhai Rajwadi Hi I want to discuss regarding Share market tips Please call me on 9998485100 .....
- Comment on Kenneth Andrade reveals his latest stock picks & strategy for 2024. He is very bullish about Pharma, Liquor and Metal stocks but is avoiding banking stocks by Shaileshbhai Rajwadi I am interested for daily call Please call me .....
Latest Stock Research Reports
- TVS Motor: Healthy Volume Growth: Karvy Valuation & Rating: In view of TVSL gaining market shares, better industry outlook and healthy exports, we increase our volume estimates by 8% and 9.5% for FY15 and FY16, accordingly we increa .....
- Buy TVS Motor; target of Rs 175: Sharekhan The TVS management is looking to leverage on a complete scooter portfolio in FY2015. It also expects motorcycle volumes, which were lacklustre in FY2014, to pick up in FY2015 aided especially by th .....
- Dish TV has several catalysts: Goldman Sachs Several catalysts lined up; Favorable risk-reward; Maintain Buy Source of opportunity We retain our Buy on Dish TV as we expect the company to benefi .....
Latest Discussions In The Forum
- Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr. M-Cap is ₹5800 Cr. Promoters hold 46%. Co operates in 3 areas i.e. Xanthine derivatives, API & C .....
- PNB Housing is undergoing a transformation to morph into a franchise that will be stronger PNB Housing is undergoing a transformation to morph into a franchise that will be stronger, more resilient & with high predictability in earnings trajectory. Risk-reward profile is favorable for a .....
- Piramal Pharma is seeing strong momentum in CDMO. Buy for TP ₹320 (27% upside) Piramal Pharma is seeing strong momentum in CDMO. Postponement of the Biosecure Act is unlikely to cause growth related issues as China rebalancing drive by global innovators likely to continue. Other .....
Latest Research Reports
| December 9th, 2023 |
| Axis Top Picks basket gave impressive returns of 31% YoY & outperformed Nifty’s 8% return. Check new recommendations |
Based on the above themes, we recommend the following stocks: ICICI Bank, Maruti Suzuki India, State Bank of India, Lupin ltd, Federal Bank, Varun Beverages, TVS Motors, Bharti Airtel, PNC infra, ITC, Relaxo, CIE Automotive India, Bank of Baroda, Westlife Foodworld, CreditAccess Grameen, JTL Industries |
| December 3rd, 2023 |
| Cochin Shipyard to witness significant YoY growth in revenues & profitability. Buy for target price of Rs 1340: ICICI Direct |
We expect CSL to witness significant YoY growth in revenues & profitability over FY24-25E, led by execution pick-up in both the segments and increasing share of margin accretive ship-repair segment |
| December 3rd, 2023 |
| Kaynes Technology has execution superiority in a favourable ecosystem. Buy for target price of Rs 2850: HDFC Sec |
Kaynes Technology (Kaynes) is one of the prominent players in electronics system design and manufacturing (ESDM) services with three decades of experience (mainly in B-B). |
| December 2nd, 2023 |
| Amara Raj is in value zone with attractive risk reward. Buy for target price of Rs 900 (27% upside) |
With steady growth prospects in base business, increasing focus in new energy domain, merger of related businesses at fair value, healthy net cash positive B/S & inexpensive valuations, we have a positive view on the stock |
| December 2nd, 2023 |
| Pitti Engineering: Strategic operation will support improving ROE and ROCE to 25.8% and 26.7%. Buy for target price of Rs 915 (40% upside) |
We initiate coverage on Pitti Engineering Ltd. (PEL) with a BUY recommendation. Our recommendation is supported by a) The company’s increasing capacity b) Its increasing share of value-added products, and c) Its expanding global footprints |
| November 26th, 2023 |
| Review of 9 Specialty Chemical Stocks And 3 Stock Recommendations by Axis Securities |
Structural story of Indian Chemical industry remains strong with strategic portfolio composition to gain export market share, and strong domestic demand we expect revenue growth to gain momentum from FY25 onward. Given the changing landscape and growing reliance on India by international customers, we expect rapid growth in this sector over the coming period as conditions stabilize |
| November 25th, 2023 |
| Pharma is back on Growth Track. Axis Securities recommends 3 top picks in the Pharma universe |
Q2FY24 Pharma Review – Higher Profitability with Easing Price Erosion, New Launches, and Lower RM Prices |
| November 25th, 2023 |
| LIC: Upgrade to BUY – Undemanding valuation; structural issues priced-in: Emkay |
We upgrade the stock to BUY, as we believe higher surplus generation and slower growth could lead to a step jump in dividend, as solvency is healthy. |
| November 25th, 2023 |
| PSP Projects has a sturdy foundation & promising future prospects. Buy for target price of Rs 905: SMIFS |
Additionally, well-managed balance sheet, strict working capital controls, and healthy return ratios are added positives. Given the favourable outlook, we initiate coverage with a Target Price of Rs905/share (15x Sept’25 estimated EPS), representing an upside potential of ~20% |
| November 19th, 2023 |
| Royal Orchid Hotels will outpace peers & narrow valuation gap with its peers. Buy for target price of Rs 498 (76% upside): Nuvama |
Strong room addition pipeline one of the key growth drivers. Expect revenue/EBITDA to clock 29%/18% CAGR over FY23–25 |